figshare
Browse
ionc_a_1979248_sm6861.docx (1.07 MB)

Impact of RBE variations on risk estimates of temporal lobe necrosis in patients treated with intensity-modulated proton therapy for head and neck cancer

Download (1.07 MB)
journal contribution
posted on 2021-09-17, 17:20 authored by Grete May Engeseth, Liv Bolstad Hysing, Pablo Yepes, Helge Egil Seime Pettersen, Radhe Mohan, Clifton Dave Fuller, Camilla Hanquist Stokkevåg, Richard Wu, Xiaodong Zhang, Steven Jay Frank, Gary Brandon Gunn

Temporal lobe necrosis (TLN) is a potential late effect after radiotherapy for skull base head and neck cancer (HNC). Several photon-derived dose constraints and normal tissue complication probability (NTCP) models have been proposed, however variation in relative biological effectiveness (RBE) may challenge the applicability of these dose constraints and models in proton therapy. The purpose of this study was therefore to investigate the influence of RBE variations on risk estimates of TLN after Intensity-Modulated Proton Therapy for HNC.

Seventy-five temporal lobes from 45 previously treated patients were included in the analysis. Sixteen temporal lobes had radiation associated Magnetic Resonance image changes (TLIC) suspected to be early signs of TLN. Fixed (RWDFix) and variable RBE-weighed doses (RWDVar) were calculated using RBE = 1.1 and two RBE models, respectively. RWDFix and RWDVar for temporal lobes were compared using Friedman’s test. Based on RWDFix, six NTCP models were fitted and internally validated through bootstrapping. Estimated probabilities from RWDFix and RWDVar were compared using paired Wilcoxon test. Seven dose constraints were evaluated separately for RWDFix and RWDVar by calculating the observed proportion of TLIC in temporal lobes meeting the specific dose constraints.

RWDVar were significantly higher than RWDFix (p < 0.01). NTCP model performance was good (AUC:0.79-0.84). The median difference in estimated probability between RWDFix and RWDVar ranged between 5.3% and 20.0% points (p < 0.01), with V60GyRBE and DMax at the smallest and largest differences, respectively. The proportion of TLIC was higher for RWDFix (4.0%–13.1%) versus RWDVar (1.3%–5.3%). For V65GyRBE ≤ 0.03 cc the proportion of TLIC was less than 5% for both RWDFix and RWDVar.

NTCP estimates were significantly influenced by RBE variations. Dmax as model predictor resulted in the largest deviations in risk estimates between RWDFix and RWDVar. V65GyRBE ≤ 0.03 cc was the most consistent dose constraint for RWDFix and RWDVar.

Funding

Engeseth received funding from Trond Mohn Foundation [TMS:BFS2017TMT07]. Dr. Fuller received/receives direct funding and salary support during the period of study execution from: the National Institutes of Health (NIH) NIBIB Research Education Programs for Residents and Clinical Fellows Grant [R25EB025787-01]; NIDCR Academic Industrial Partnership Grant [R01DE028290]; NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program [1R01CA218148]; an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program [P30CA016672-44]; and an NSF Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant [NSF 1933369]. Dr. Fuller has received direct industry grant support, honoraria, and travel funding from Elekta AB unrelated to this project. Direct infrastructure support is provided by the multidisciplinary the Radiation Oncology/Cancer Imaging Program [P30CA016672-44] of the MD Anderson Cancer Center Support Grant [P30CA016672] and the MD Anderson Program in Image-guided Cancer Therapy.

History